NCT04294628 - Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Advanced Malignant Solid NeoplasmHER2-Positive Breast CarcinomaMetastatic Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm

Interventions

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Echocardiography Test

Undergo ECHO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

BIOLOGICAL

Trastuzumab Deruxtecan

Given IV

Trial Locations (6)

10065

NYP/Weill Cornell Medical Center, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

20892

National Cancer Institute Developmental Therapeutics Clinic, Bethesda

National Institutes of Health Clinical Center, Bethesda

43210

Ohio State University Comprehensive Cancer Center, Columbus

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH